Surefire Medical is pleased to announce the appointment of Anil Singhal, PhD, to its board of directors. With an already strong drug delivery foundation, Surefire is looking to deepen its leadership capabilities in oncology with new research and a pipeline of proprietary technology. Dr. Singhal brings extensive experience in oncology to Surefire Medical and will work to accelerate the development and application of Pressure-enabled Drug Delivery ™ technology to make a significant impact in cancer care.
Dr. Singhal currently serves as acting chief scientific officer for OncoResponse, a company focused on the development of therapeutic antibodies for cancer, and serves as executive in residence for Canaan Partners, focused on early stage healthcare and technology. Previously, Dr. Singhal led early-stage oncology drug development at AbbVie, served as an executive medical director for Facet Biotech, and has held various roles in oncology research at several pharmaceutical and biotech organizations.
Dr. Singhal is also a member of the American Society of Clinical Oncology, the American Society of Hematology, and is a board member for the California Life Sciences Association.
Read the press release for more information on Dr. Singhal.